Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00

Key Points

• Wedbush lowered its price target for Larimar Therapeutics from $12 to $11 while maintaining an “outperform” rating. The new target implies 167.64% upside from the prior close.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $12.57, despite ratings ranging from strong buy to sell.
• Larimar reported quarterly EPS of -$0.30, beating the consensus estimate of -$0.38. Shares opened at $4.11 and were up 3.3%, while institutional investors own 91.92% of the company.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) had its price objective reduced by equities research analysts at Wedbush from $12.00 to $11.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Wedbush's price objective suggests a potential upside of 167.64% from the stock's previous close.

Several other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. initiated coverage on shares of Larimar Therapeutics in a research note on Wednesday, May 27th. They set an "overweight" rating and a $9.00 price objective on the stock. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 30th. Robert W. Baird cut their price target on Larimar Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, June 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Larimar Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen raised Larimar Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $12.57.

Larimar Therapeutics Trading Up 3.3%

Shares of LRMR stock opened at $4.11 on Wednesday. The company has a market capitalization of $426.95 million, a price-to-earnings ratio of -2.00 and a beta of 0.81. The firm has a 50-day moving average price of $3.60 and a 200 day moving average price of $3.97. Larimar Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.42.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.08. As a group, research analysts predict that Larimar Therapeutics will post -1.65 earnings per share for the current year.

Insider Transactions at Larimar Therapeutics

In other Larimar Therapeutics news, Director Thomas Edward Hamilton bought 50,000 shares of the business's stock in a transaction dated Monday, July 6th. The shares were acquired at an average price of $3.34 per share, with a total value of $167,000.00. Following the purchase, the director owned 714,798 shares in the company, valued at approximately $2,387,425.32. The trade was a 7.52% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LRMR. BNP Paribas Financial Markets grew its stake in shares of Larimar Therapeutics by 75.8% in the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company's stock valued at $33,000 after buying an additional 4,376 shares in the last quarter. American Century Companies Inc. lifted its position in Larimar Therapeutics by 7.8% during the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock worth $200,000 after acquiring an additional 5,001 shares in the last quarter. Sei Investments Co. lifted its position in Larimar Therapeutics by 54.5% during the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company's stock worth $74,000 after acquiring an additional 5,763 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Larimar Therapeutics by 26.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company's stock worth $111,000 after acquiring an additional 6,038 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Larimar Therapeutics by 17.0% in the 1st quarter. Bank of America Corp DE now owns 47,359 shares of the company's stock worth $213,000 after acquiring an additional 6,886 shares during the period. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source